UKPDS Paper 36 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes Trials Unit UKPDS slides are made freely available to non-profit organisations on the understanding that the contents are not altered in any way, other than for translation into other languages Commercial organisations wishing to use UKPDS slides should contact the UKPDS Administrator UKPDS 36. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study. British Medical Journal 2000; 321:

Any Diabetes Related Endpoint 12% decrease per 10 mm Hg decrement in BP p< Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

17% decrease per 10 mm Hg decrement in BP p< Diabetes Related Deaths Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

12% decrease per 10 mm Hg decrement in BP p< All Cause Mortality Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

12% decrease per 10 mm Hg decrement in BP p< Fatal and Non-Fatal Myocardial Infarction Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

19% decrease per 10 mm Hg decrement in BP p= Fatal and Non-Fatal Stroke Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

13% decrease per 10 mm Hg decrement in BP p= Microvascular Endpoints Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

p= Cataract Extraction Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

16% decrease per 10 mm Hg decrement in BP p< Amputation or Death from Peripheral Vascular Disease Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

12% decrease per 10 mm Hg decrement in BP p= Heart Failure Updated mean systolic blood pressure Hazard ratio UKPDS 36. BMJ 2000; 321:

UKPDS 35. BMJ 2000; 321: Myocardial Infarction and Microvascular Disease

UKPDS 36 Summary There is a direct relationship between the risk of complications of diabetes and systolic blood pressure over time No threshold of systolic blood pressure was observed for a substantive change in risk for any of the clinical outcomes examined The lower the systolic blood pressure the lower the risk for complications There may be additional risk reduction with angiotensin converting enzyme inhibitors and beta blockers over and above that associated with the lowering of blood pressure